Cargando…

Topical Sirolimus 0.2% Gel for the Management of Tuberous Sclerosis Complex-Related Cutaneous Manifestations: An Interim Analysis of Postmarketing Surveillance in Japan

INTRODUCTION: Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic disorder affecting several organs, including skin. We sought to assess the real-world effectiveness and safety of a topical sirolimus 0.2% gel treatment for TSC-related cutaneous manifestations. METHODS: We conducted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Egami, Akemi, Takahashi, Shinji, Kokubo, Takeshi, Boggarapu, Sreedevi, Beresford, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149422/ https://www.ncbi.nlm.nih.gov/pubmed/36905480 http://dx.doi.org/10.1007/s13555-023-00914-2

Ejemplares similares

Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database
por: Boggarapu, Sreedevi, et al.
Publicado: (2022)

Facial Angiofibromas of Tuberous Sclerosis Treated with Topical Sirolimus in an Indian Patient
por: Vasani, Resham J
Publicado: (2015)

Early Sirolimus Gel Treatment May Diminish Angiofibromas and Prevent Angiofibroma Recurrence in Children With Tuberous Sclerosis Complex
por: Okanishi, Tohru, et al.
Publicado: (2020)

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
por: Koike, Takao, et al.
Publicado: (2011)

Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role
por: Cardis, Michael A, et al.
Publicado: (2017)

Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex
por: Amin, S., et al.
Publicado: (2017)

Initial Dosage Recommendation for Sirolimus in Children With Tuberous Sclerosis Complex
por: Wang, Dong-Dong, et al.
Publicado: (2020)

Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex
por: Hatano, Takashi, et al.
Publicado: (2020)

Folliculocystic and Collagenous Hamartoma: A Rare Cutaneous Manifestation of Tuberous Sclerosis
por: Shajil, Chandana, et al.
Publicado: (2022)

Sirolimus in Infants with Multiple Cardiac Rhabdomyomas Associated with Tuberous Sclerosis Complex
por: Lucchesi, Maurizio, et al.
Publicado: (2018)

Topical rapamycin (sirolimus) for facial angiofibromas
por: Madke, Bhushan
Publicado: (2013)

Cutaneous Manifestations of Sarcoidosis Seen in a Patient with a History of Tuberous Sclerosis
por: Bernacki, Seth, et al.
Publicado: (2023)

Sirolimus therapy for fetal cardiac rhabdomyoma in a pregnant woman with tuberous sclerosis
por: Park, Hyea, et al.
Publicado: (2019)

Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex: A Double-Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of Topically Applied Rapamycin
por: Koenig, Mary Kay, et al.
Publicado: (2012)

Comparative evaluation of topical application of turmeric gel and 0.2% chlorhexidine gluconate gel in prevention of gingivitis
por: Singh, Vibha, et al.
Publicado: (2015)

Long-term efficacy and safety of sirolimus for retinal astrocytic hamartoma associated with tuberous sclerosis complex
por: Zhang, Chen-Xi, et al.
Publicado: (2022)

Recent topics related to etiology and clinical manifestations of cutaneous arteritis
por: Ikeda, Takaharu
Publicado: (2022)

Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
por: Yamashita, Takeshi, et al.
Publicado: (2018)

Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance
por: Sasaki, Ritsue, et al.
Publicado: (2019)

Renal Manifestations of Tuberous Sclerosis Complex
por: Nair, Nikhil, et al.
Publicado: (2020)

Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China
por: Luo, Cong, et al.
Publicado: (2021)

Sirolimus-Induced Regression of Tuberous Sclerosis–Associated Cardiac Rhabdomyoma Causing Left Ventricular Outflow Tract Obstruction
por: Winkie, Colin, et al.
Publicado: (2022)

Safety of Sirolimus in Patients with Tuberous Sclerosis Complex under Two Years of Age—A Bicenter Retrospective Study
por: Śmiałek, Dominika, et al.
Publicado: (2023)

Successful Amelioration of Inflammatory Linear Verrucous Epidermal Nevus with Topical Sirolimus
por: Patel, Nayankumar, et al.
Publicado: (2020)

Yet another pulmonary manifestation of tuberous sclerosis
por: Bhawna, Satija, et al.
Publicado: (2014)

Cutaneous Lesions as the Sole Presentation of Tuberous Sclerosis
por: Ahmed, Mohanad, et al.
Publicado: (2020)

Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study
por: Kaneko, Shuichi, et al.
Publicado: (2016)

Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations
por: Freitas, Carolina Salim Gonçalves, et al.
Publicado: (2015)

Recalcitrant primary cutaneous Rosai‐Dorfman disease. Efficacy of sirolimus and intralesional methylprednisolone
por: Tirado‐Sánchez, Andrés
Publicado: (2023)

Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan
por: Sugamori, Haruko, et al.
Publicado: (2022)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
por: Sullivan, John T.
Publicado: (2022)

Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease
por: Gupta, Pawan Kumar, et al.
Publicado: (2021)

Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017)

Neuro-ophthalmological manifestations of tuberous sclerosis: current perspectives
por: Wan, Michael J, et al.
Publicado: (2019)

Postmarketing Safety Study Tool: A Web Based, Dynamic, and Interoperable System for Postmarketing Drug Surveillance Studies
por: Sinaci, A. Anil, et al.
Publicado: (2015)

Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease
por: Dabora, Sandra L., et al.
Publicado: (2011)

Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis
por: Malinowska, Izabela A., et al.
Publicado: (2013)

Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens
por: Kirby, Sean, et al.
Publicado: (2012)

Population Pharmacokinetics and Initial Dose Optimization of Sirolimus Improving Drug Blood Level for Seizure Control in Pediatric Patients With Tuberous Sclerosis Complex
por: Chen, Xiao, et al.
Publicado: (2021)

The Importance of Registries in the Postmarketing Surveillance of Surgical Meshes
por: Köckerling, Ferdinand, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0ft8mve0qnpobpchahrr3ddii8